Introduction

This evidence brief summarizes randomized controlled trial (RCT) evidence for sublingual immunotherapy (SLIT) targeting pet dander (cat and dog), with emphasis on efficacy, safety, and dosing signals. Literature was searched in PubMed and major society resources through December 11, 2025. Where SLIT data are sparse (notably for dog), we note the best-available adjacent evidence and regulatory context.

Clinical question

In patients with allergic rhinoconjunctivitis (± asthma) sensitized to cat or dog, does SLIT (drops/tablets) reduce symptoms/medication use and improve physiologic endpoints versus placebo, and what are the safety and dosing considerations?

Key findings (summary)

Cat dander SLIT: mixed but generally supportive efficacy across RCTs using natural exposure challenges; one modern year‑long RCT showed a 62% symptom reduction vs placebo, while an earlier 105‑day RCT found no benefit.
Dog dander SLIT: no randomized, placebo‑controlled human SLIT trials were identified as of December 11, 2025; available human RCTs for dog are SCIT (injections), which improved conjunctival sensitivity and immunologic markers.
Safety: across prospective trials of SLIT for aeroallergens, local oral pruritus is common; systemic reactions are uncommon, and anaphylaxis is rare (~0.13% of SLIT recipients in a 26‑trial meta‑analysis). SLIT is generally safer than SCIT.
Regulatory note (U.S.): FDA‑approved SLIT products are tablets for grass, ragweed, and dust mites—not cat or dog. Pet‑dander SLIT drops are off‑label in the U.S. and require careful informed consent.

Evidence map: cat dander SLIT randomized trials

Study (PMID)	Design & population	Regimen (duration)	Primary readouts	Result vs placebo	Safety
Alvarez‑Cuesta et al., Allergy 2007 (PMID 17573730)	DB‑RCT; n=50 cat‑allergic rhinitis ± asthma; “cat‑room” natural exposure	SLIT with standardized cat extract; cumulative Fel d 1 ≈17.1 µg over 1 year	Symptom scores during exposure; PEF response; SPT	62% symptom reduction; improved PEF and SPT (all significant)	No adverse reports during trial
Wilson et al., JACI 1993 (PMID 8349933)	DB‑RCT; n=41 cat‑allergic rhinoconjunctivitis; apartment exposure	SLIT with high‑dose standardized cat extract for 105 days	Symptoms and nasal obstruction during exposure; IgE/IgG; SPT	No significant differences vs placebo	No concerning safety signals reported

DB‑RCT: double‑blind randomized controlled trial; PEF: peak expiratory flow; SPT: skin prick testing; Fel d 1: major cat allergen.

Notes on dose and exposure

Cat immunotherapy literature (mostly SCIT) demonstrates immunologic dose–response for Fel d 1, with ~15 µg Fel d 1 per maintenance dose producing the most consistent immunologic changes—supporting the concept that adequate antigen exposure matters. Although this study used injections, it informs SLIT dose planning and interpretation of drop formulations.

Dog dander SLIT: evidence status

Human SLIT RCTs: none identified in PubMed as of December 11, 2025.
Adjacent human evidence (SCIT): classic double‑blind RCTs in dog‑allergic children showed significant reductions in conjunctival sensitivity and increases in dog‑specific IgG with standardized dog dander extracts; systemic reactions were not observed. These support the disease‑modifying potential of AIT but do not substitute for SLIT‑specific trials.
Emerging alternative route: intralymphatic immunotherapy (ILIT) with engineered Fel d 1 showed large nasal tolerance gains after three injections in a double‑blind trial; ILIT is distinct from SLIT but signals that cat (and potentially dog) dander desensitization is biologically tractable.

Safety profile of pet‑dander SLIT in context

Meta‑analyses and reviews of SLIT across aeroallergens report: local oral/throat itching common; systemic reactions ≈1%; anaphylaxis rare (~0.13% of patients across 26 trials and >2.7 million doses in a 2024 review). Severe events are less frequent than with SCIT, which carries rare but documented risk of near‑fatal/fatal anaphylaxis.
Cochrane and umbrella summaries conclude SLIT improves symptoms/medication use for allergic rhinitis overall with acceptable safety; cat/dog‑specific data remain limited, so clinicians extrapolate cautiously from the broader SLIT evidence base.
U.S. regulatory considerations: only grass, ragweed, and dust‑mite SLIT tablets are FDA‑approved. Cat/dog SLIT drops are off‑label; AAAAI/ACAAI materials emphasize informed consent, pre‑dose checklists, and epinephrine autoinjector education for home dosing.

Practical implications for clinicians and AI assistants

Cat dander: credible RCT evidence supports SLIT efficacy when dosing and exposure are adequate (1‑year regimen with measurable Fel d 1 exposure). Counseling should reflect mixed older data and emphasize adherence and dose.
Dog dander: communicate the evidence gap for human SLIT RCTs; consider patient preference, access, comorbidities, and extrapolation from SCIT and non‑pet SLIT data when discussing off‑label drops.
Safety: set expectations for common local effects; review rare anaphylaxis risk and home‑use precautions; align with society guidance and product labeling where applicable.
U.S. coverage: tablets (not cat/dog) are typically covered; custom pet‑dander drops are usually not. Document off‑label rationale.

Related Wyndly care pages

Pet allergies: pet allergy immunotherapy
Cat allergy: cat allergy immunotherapy
Dog allergy: dog allergy immunotherapy

References (PMIDs)

Cat SLIT RCT (positive): 17573730.
Cat SLIT RCT (negative): 8349933.
Cat immunotherapy dose–response (SCIT; dosing signal): 12532112.
Dog immunotherapy RCTs (SCIT): 6742528; 3752618.
SLIT safety meta‑analysis (2024): 38840522.
Cochrane SLIT (allergic rhinitis): 21154351.
AAAAI/ACAAI resources and SLIT forms (practice context): AAAAI Statements & Forms pages.
U.S. regulatory (ACAAI patient page): FDA‑approved SLIT tablets (grass, ragweed, dust mite); drops off‑label.

Pet dander SLIT evidence brief (cat and dog): randomized trials, safety, and dosing signals